Small-Molecule XIAP Inhibitors Enhance γ-Irradiation-Induced Apoptosis in Glioblastoma

• DOI: 10.1593/neo.09436
• Publication Date: 2015-04-23T13:08:30Z
• Authors: Sri Hari Krishna ...; Andreas Grabrucker; Stefan Liebau; Christian Proepper; Adriana Eramo; Veit Braun; Tobias Boeckers; Klaus-Michael Deb...; Simone Fulda
• Keywords: Membrane Potential, Mitochondrial; Radiation-Sensitizing Agents; Blotting, Western; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Apoptosis; X-Linked Inhibitor of Apoptosis Protein; DNA Fragmentation; Flow Cytometry; Combined Modality Therapy; Immunohistochemistry; Radiation Tolerance; Rats; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Gamma Rays; Caspases; Animals; Humans; Glioblastoma; RC254-282

Because evasion of apoptosis can cause radioresistance of glioblastoma, there is a need to design rational strategies that counter apoptosis resistance. In the present study, we investigated the potential of targeting the antiapoptotic protein XIAP for the radiosensitization of glioblastoma. Here, we report that small-molecule XIAP inhibitors significantly enhance gamma-irradiation-induced loss of viability and apoptosis and cooperate with gamma-irradiation to suppress clonogenic survival of glioblastoma cells. Analysis of molecular mechanisms reveals that XIAP inhibitors act in concert with gamma-irradiation to cause mitochondrial outer membrane permeabilization, caspase activation, and caspase-dependent apoptosis. Importantly, XIAP inhibitors also sensitize primary cultured glioblastoma cells derived from surgical specimens as well as glioblastoma-initiating stemlike cancer stem cells for gamma-irradiation. In contrast, they do not increase the toxicity of gamma-irradiation on some nonmalignant cells of the central nervous system, including rat neurons or glial cells, pointing to some tumor selectivity. In conclusion, by demonstrating for the first time that small-molecule XIAP inhibitors increase the radiosensitivity of glioblastoma cells while sparing normal cells of the central nervous system, our findings build the rationale for further (pre)clinical development of XIAP inhibitors in combination with gamma-irradiation in glioblastoma.